Loading.
Preparing your Shotlee experience
Authenticating
Loading health data
Syncing preferences
Health
Semaglutide Fails to Slow Advancement of Alzheimer's Disease
S
Shotlee
Health & Wellness Team
2 min read
Preparing your Shotlee experience
Results from a recent trial indicate that semaglutide, typically used for obesity, did not slow the progression of Alzheimer's disease. While the drug improved Alzheimer's-related biomarkers, this did not translate to a delay in the disease's advancement. Researchers emphasize the need for multi-faceted approaches to tackle Alzheimer's.
The discouraging outcomes from a study on semaglutide are scheduled for presentation at an upcoming Alzheimer's disease conference next month. These findings are currently awaiting publication in a peer-reviewed journal.
Despite a low expectation of success, a responsibility to explore semaglutide's potential was felt due to the significant unmet need in Alzheimer's disease and several indicative data points, according to Martin Holst Lange, chief scientific officer and executive vice president of research and development at Novo Nordisk.
Although semaglutide did not demonstrate effectiveness in slowing the advancement of Alzheimer's disease, the extensive evidence supporting semaglutide continues to provide benefits for those with type 2 diabetes, obesity, and related conditions, he stated.
Participants in the Evoke trials, aged 55 to 85, presented with mild cognitive impairment or mild dementia resulting from Alzheimer's disease.
Dementia progression was carefully monitored and assessed via interviews and tests.
Treatment using semaglutide resulted in an improvement of Alzheimer's disease-related biomarkers. However, this **improvement did not lead to a delay in the progression** of the disease.
These trial outcomes serve as another reminder that several different biological processes drive Alzheimer's, said Dr. Kohlhaas. It's unlikely that a single approach will be sufficient.
The field must now concentrate on gaining a deeper understanding of these processes and creating therapies that can be utilized in conjunction to combat the disease from numerous perspectives.
Fiona Carragher, chief policy and research officer at Alzheimer's Society, stated that while these eagerly awaited results were "very disappointing", every investigation aids in the development of better drugs and the design of improved trials in the future.
Currently, there are over 130 Alzheimer's medications undergoing clinical trials, with approximately 30 in late-stage trials - the final phase before regulatory consideration. Health tracking apps like Shotlee can help monitor subtle cognitive changes that may be relevant in such trials.
⚠️ Disclaimer: This article is for informational purposes only. Consult your healthcare provider before starting any medication or supplement.
Original content from BBC
View Original Article
An affordable and readily accessible medication is gaining attention as a potential solution for curbing alcohol cravings, drawing comparisons to the way GLP-1 drugs manage food cravings. Naltrexone, by impacting dopamine-reward pathways, reduces the satisfying feeling associated with alcohol consumption, thus diminishing the desire for it. Research and anecdotal evidence suggest it could be a game-changer for many.
Mounjaro, a drug by Eli Lilly, is set to be included in China's state-run health insurance program for individuals with type 2 diabetes starting January 1. This inclusion aims to improve access to the medication, although increased sales may be balanced by reduced prices. The drug was introduced in China earlier this year.
The World Health Organization (WHO) has provided new guidance on using GLP-1 drugs like Ozempic and Wegovy for obesity. The recommendations include considerations for adults and highlight the importance of lifestyle changes alongside medication.
Monitor GLP-1 medications, peptide therapy, weight loss, and wellness metrics with our comprehensive health tracking app. Join thousands of users taking control of their health!
Start Tracking Free Forever! ✨